Tous Actualités
Suivre
Abonner Pieris AG

Pieris AG

Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
Anti-VEGF PRS-050 is first Anticalin tested in humans

Freising-Weihenstephan (ots)

Pieris AG announced today the
initiation of a Phase I clinical trial in cancer patients for its 
lead program, PRS-050, an anti-VEGF Anticalin. The trial is an 
open-label, dose-escalating evaluation of the compound's safety and 
tolerability in patients with solid tumors. Conducted at three sites 
in Germany, the trial is underway and patients from the first cohort 
have been dosed.
"Meeting our goal of initiating this trial in the first half of 
2010 demonstrates Pieris' commitment to establishing the safety and 
the therapeutic relevance of the Anticalin drug class," stated 
Stephen Yoder, CEO of Pieris. "Further, the high potency observed in 
preclinical studies, together with the small size and the lack of an 
antibody Fc domain, show promise of an attractive combined efficacy 
and safety profile for PRS-050."
The trial is designed to test PRS-050 in approximately 40 
patients, who will receive the compound and then be monitored for 
safety and tolerability. The patients recruited for the trial are 
cancer patients with advanced, recurrent or metastatic solid tumors, 
refractory to standard therapy.
PRS-050 is an anti-VEGF (Vascular Endothelial Growth Factor) 
Anticalin discovered and developed internally at the company from 
Pieris' proprietary Anticalin libraries. PRS-050's mechanism of 
action is based on its ability to bind the VEGF ligand, thereby 
inhibiting tumor growth. VEGF's role in cancer angiogenesis, the 
mechanism by which cancer tumors increase blood vessel development to
deliver key nutrients and oxygen is well established, both 
scientifically and clinically.
About Pieris
Pieris AG is an independent biotechnology company advancing its 
proprietary Anticalin(r) technology to create safer, more efficacious
and more convenient protein therapeutics. Exclusive to Pieris, 
Anticalin-based drugs promise to address high-unmet medical needs and
expand the therapeutic potential of current targeted approaches.  
Pieris' pipeline ranges from its lead clinical program (anti-VEGF, 
oncology), to multiple Anticalins in preclinical development.  Pieris
will commercialize Anticalin therapeutics through strategic 
partnerships, involving both its proprietary pipeline and its de novo
drug discovery capabilities. Its most recent partnership is with 
Allergan, Inc. (NYSE: AGN), focusing on novel treatments for eye 
diseases. Privately held, Pieris has been funded by premier 
biotechnology-focused venture capital, including lead investors 
OrbiMed Advisors and Global Life Science Ventures.
For more information, please contact:
Pieris AG, 
Stephen Yoder, CEO 
+49 (0) 8161 1411 400,  
info@pieris-ag.com

Plus de actualités: Pieris AG
Plus de actualités: Pieris AG
  • 07.06.2010 – 10:17

    Pieris AG Appoints Chief Scientific Officer

    Freising-Weihenstephan (ots) - Pieris AG announced today that Laurent Audoly, Ph.D., has joined the company as Chief Scientific Officer, effective immediately. Dr. Audoly, most recently Biologics Research Site Lead at Merck & Co. Inc., brings both pharma and biotech experience, with extensive expertise in therapeutic protein drug development. "Laurent has an impressive track record of leading teams and ...

  • 30.04.2010 – 10:28

    Pieris Announces Positive Preclinical Data on c-Met Anticalin Drug Program

    Freising-Weihenstephan (ots) - Novel Approach with PRS-110 Shows Dose-dependent Response in Cancer Model Pieris AG announced today preclinical data for its proprietary PRS-110 Anticalin" compound, which targets the c-Met receptor, demonstrating a dose-dependant reduction of tumor growth in a xenograft mouse model. The results provide an indication that an ...